Patient characteristics
| UPN . | Disease phenotype . | Diagnosis . | Cytogenetics . | Age, y/Sex . | Donor . | Date of allogeneic alloTCD-HSCT . | Outcome, survival after alloTCD-HSCT (mo) . | Current disease status . |
|---|---|---|---|---|---|---|---|---|
| 1 | IgG K | ISS stage I | 1q23; 19p13; MLL | 48/M | MRD (10/10) | 10/28/2010 | Alive (23.3) | Stable VGPR |
| 2 | IgA K | Del13q; 14q32 | 46/F | MRD (10/10) | 1/15/2010 | Alive (32.8) | PR | |
| 3 | IgG Λ | ISS stage III, Durie Salmon stage IIIA | 11q23; t(4:14); del17p | 54/F | MRD (10/10) | 10/23/2009 | Alive (35.6) | POD |
| 4 | IgG K | t(4;14); del13q; del16 | 48/F | MUD (10/10) | 6/23/2010 | Alive (27.5) | CR | |
| 5 | IgA K | Trisomy 3, 15,9; del4,12,14 | 48/M | MRD (10/10) | 12/17/2009 | Alive (33.8) | POD | |
| 6 | IgA K | ISS stage I | del13q; 1q25; 11q23 | 68/M | MRD (10/10) | 1/21/2010 | Deceased (26.8) | N/A |
| 7 | IgA Λ | Stage III | t(4;14); 13q | 38/M | MRD (10/10) | 6/18/2008 | Alive (52) | CR |
| 8 | IgG K | Stage III | N/A | 42/M | MMUD (9/10, DQ) | 11/28/2007 | Alive (58.8) | Stable VGPR |
| 9 | IgG Λ | Stage III | del17p; del13q; t(4;14) | 57/M | MUD (10/10) | 3/4/2009 | Alive (43.4) | CR |
| 10 | IgG K | Stage II | Del13; (MLL; 11q23) | 32/M | MUD (10/10) | 8/20/2008 | Alive (49.9) | PR |
| UPN . | Disease phenotype . | Diagnosis . | Cytogenetics . | Age, y/Sex . | Donor . | Date of allogeneic alloTCD-HSCT . | Outcome, survival after alloTCD-HSCT (mo) . | Current disease status . |
|---|---|---|---|---|---|---|---|---|
| 1 | IgG K | ISS stage I | 1q23; 19p13; MLL | 48/M | MRD (10/10) | 10/28/2010 | Alive (23.3) | Stable VGPR |
| 2 | IgA K | Del13q; 14q32 | 46/F | MRD (10/10) | 1/15/2010 | Alive (32.8) | PR | |
| 3 | IgG Λ | ISS stage III, Durie Salmon stage IIIA | 11q23; t(4:14); del17p | 54/F | MRD (10/10) | 10/23/2009 | Alive (35.6) | POD |
| 4 | IgG K | t(4;14); del13q; del16 | 48/F | MUD (10/10) | 6/23/2010 | Alive (27.5) | CR | |
| 5 | IgA K | Trisomy 3, 15,9; del4,12,14 | 48/M | MRD (10/10) | 12/17/2009 | Alive (33.8) | POD | |
| 6 | IgA K | ISS stage I | del13q; 1q25; 11q23 | 68/M | MRD (10/10) | 1/21/2010 | Deceased (26.8) | N/A |
| 7 | IgA Λ | Stage III | t(4;14); 13q | 38/M | MRD (10/10) | 6/18/2008 | Alive (52) | CR |
| 8 | IgG K | Stage III | N/A | 42/M | MMUD (9/10, DQ) | 11/28/2007 | Alive (58.8) | Stable VGPR |
| 9 | IgG Λ | Stage III | del17p; del13q; t(4;14) | 57/M | MUD (10/10) | 3/4/2009 | Alive (43.4) | CR |
| 10 | IgG K | Stage II | Del13; (MLL; 11q23) | 32/M | MUD (10/10) | 8/20/2008 | Alive (49.9) | PR |
UPN indicates unidentified patient number; Ig, immunoglobulin; ISS, international staging system; MLL, mixed-lineage leukemia gene; del, deletion; t, translocation; F, female; M, male; MRD, matched related donor; MUD, matched unrelated donor; MMUD, mismatched unrelated donor; VGPR, very good partial response; PR, partial response; POD, progression of disease; and CR, complete remission.